ANI Pharmaceuticals AI Stock Analysis
Want to see ANIP full AI Analyst Report?
ANI Pharmaceuticals (ANIP) AI Stock Analysis
ANI Pharmaceuticals
(NASDAQ:ANIP)
Overall score is driven by strong financial performance (scaled revenue, improved margins, and solid free cash flow) and a generally positive earnings outlook with raised profitability guidance. These strengths are partially offset by weak technical momentum (price below key moving averages and negative MACD) and execution/transaction risks tied to Cortrophin conversion issues and acquisition-related dilution and leverage.
ANI Pharmaceuticals (ANIP) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.59B
- Dividend Yield
- ―
- Average Volume (3M)
- 416.33K
- Price to Earnings (P/E)
- 13.5
- Beta (1Y)
- 0.50
- Revenue Growth
- 25.94%
- EPS Growth
- 203.25%
- Country
- US
- Employees
- 970
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
ANI Pharmaceuticals Business Overview & Revenue Model
Company Description
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel,...
How the Company Makes Money
ANI Pharmaceuticals generates revenue primarily from sales of prescription pharmaceutical products. A major component is net product revenue from its branded portfolio (where the company markets and sells its own branded medicines and records revenue...
ANI Pharmaceuticals Earnings Call Summary
The call was predominantly positive, with strong revenue, EBITDA, EPS, cash flow, generics performance, ILUVIEN growth, and raised full-year profitability guidance. ANI also highlighted the strategic and commercial potential of the Aegidus acquisition and emcetate. The main negatives were the Cortrophin revenue-conversion issues, reduced Cortrophin guidance, and expected first-year dilution from the acquisition.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management expects 2026 total company net revenue of $1.085 billion to $1.125 billion, representing 25% year over year growth; Cortrophin Gel net revenue of $480 million to $500 million; ILUVIEN net revenue of $80 million to $85 million; adjusted non GAAP EBITDA of $290 million to $300 million; non GAAP earnings per share between $9.37 and $9.71 per share; adjusted gross margin in the range of 60.3% to 61%; 21.5 million and 21.8 million shares outstanding; and a full year US GAAP effective tax rate of approximately 27% to 29%, with fourth quarter revenues from the generics and Other segment expected to be relatively similar to the third quarter revenues posted this morning; the Aegidus deal is expected to close in late 26 or early 27, with trailing 12 month pro forma net leverage of approximately 2.7x, and low single digit royalty income from sales of WAKIX.
ANI Pharmaceuticals Financial Statement Overview
Summary
Strong recent fundamentals: revenue scaled materially (to ~$1.04B TTM), profitability improved to ~10.8% net margin TTM with solid ~17.4% EBIT margin, and cash generation is robust ($205M FCF TTM). Key offset is historical volatility (loss years and cash-flow swings) and debt coverage still under 1x via operating cash flow, requiring sustained execution.
Income Statement
82Very PositiveBalance Sheet
70PositiveCash Flow
78Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.04B | 883.37M | 614.38M | 486.82M | 316.38M | 216.14M |
| Gross Profit | 705.65M | 450.64M | 364.17M | 305.30M | 177.60M | 115.53M |
| EBITDA | 270.86M | 207.27M | 63.12M | 106.60M | 25.04M | 3.12M |
| Net Income | 116.84M | 78.34M | -18.52M | 18.78M | -47.90M | -42.60M |
Balance Sheet | ||||||
| Total Assets | 1.57B | 1.44B | 1.28B | 904.42M | 760.09M | 771.60M |
| Cash, Cash Equivalents and Short-Term Investments | 436.35M | 285.58M | 151.17M | 221.12M | 48.23M | 100.30M |
| Total Debt | 297.68M | 325.19M | 624.09M | 285.67M | 286.52M | 287.37M |
| Total Liabilities | 930.55M | 899.65M | 855.17M | 446.82M | 421.55M | 412.86M |
| Stockholders Equity | 637.11M | 540.72M | 428.53M | 457.60M | 338.54M | 358.74M |
Cash Flow | ||||||
| Free Cash Flow | 177.46M | 150.90M | 47.06M | 100.45M | -47.66M | -20.32M |
| Operating Cash Flow | 229.20M | 185.22M | 64.02M | 118.96M | -31.20M | 3.32M |
| Investing Cash Flow | -29.28M | -34.32M | -404.72M | -18.51M | -15.74M | -105.48M |
| Financing Cash Flow | -40.73M | -9.94M | 264.94M | 67.44M | -5.13M | 194.59M |
ANI Pharmaceuticals Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANIP, the sentiment is Negative. The current price of 69.99 is below the 20-day moving average (MA) of 71.22, below the 50-day MA of 72.30, and below the 200-day MA of 76.90, indicating a bearish trend. The MACD of -0.59 indicates Negative momentum. The RSI at 44.73 is Neutral, neither overbought nor oversold. The STOCH value of 41.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ANIP.
ANI Pharmaceuticals Risk Analysis
ANI Pharmaceuticals disclosed 80 risk factors in its most recent earnings report. ANI Pharmaceuticals reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
3 New RisksANI Pharmaceuticals Peers Comparison
Overall Rating
ETON79Outperform
AMPH77Outperform
ANIP72Outperform
COLL69Neutral
SUPN63Neutral
AMRX58Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 79Outperform | $1.84B | 35.66 | 104.82% | ― | 100.61% | ― | |
| 77Outperform | $1.24B | 12.87 | 12.59% | ― | 3.11% | -4.26% | |
| 72Outperform | $1.59B | 13.52 | 20.00% | ― | 25.94% | 203.25% | |
| 69Neutral | $793.98M | 20.85 | 12.49% | ― | 7.68% | -34.31% | |
| 63Neutral | $6.07B | 7.95 | -352.94% | ― | 16.44% | 265.06% | |
| 58Neutral | $7.36B | 48.70 | 131.71% | ― | 8.88% | 2272.07% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ANIP | Ani Pharmaceuticals | 69.99 | -8.53 | -10.86% | |
| SUPN | Supernus, Inc. | 29.04 | 4.39 | 17.81% | |
| AMPH | Amphastar Pharmaceuticals Inc | 29.10 | 3.74 | 14.75% | |
| COLL | Collegium Pharmaceutical Inc. | 25.55 | -18.40 | -41.87% | |
| AMRX | Amneal Pharma | 21.12 | 9.61 | 83.41% | |
| ETON | Eton Pharmaceuticals | 63.65 | 47.35 | 290.49% |
ANI Pharmaceuticals Corporate Events
ANI Pharmaceuticals Announces Proposed Acquisition of Egetis Therapeutics
PositiveOn November 4, 2026, ANI Pharmaceuticals entered into a 364-day senior bridge credit facility with lenders and JPMorgan Chase Bank as administrative agent. The facility provided for borrowings of up to $676 million and was entered into in connection...
ANI Pharmaceuticals Reports Strong Third-Quarter Results, Expands Rare Disease Portfolio
PositiveOn November 5, 2026, ANI Pharmaceuticals reported third-quarter revenue of $290.8 million, up 27.6% year over year, with GAAP net income of $35.1 million and adjusted non-GAAP EBITDA of $83.3 million. Cortrophin Gel revenue rose 36.1% to $138.7 milli...
ANI Pharmaceuticals reshapes board to advance rare disease strategy
PositiveOn August 19, 2026, ANI Pharmaceuticals appointed veteran dealmaker and strategist Henry Gosebruch to its Board of Directors, with his term running through the 2027 annual meeting of stockholders. The company highlighted his more than 30 years of bio...
ANI Pharmaceuticals Posts Record Q2 2026 Results
PositiveANI Pharmaceuticals reported record second-quarter 2026 results on August 7, 2026, with total net revenues rising 25.9% year-over-year to $266.0 million and GAAP net income to common shareholders reaching $24.7 million. Growth was led by Purified Cor...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026
